Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Central Hospital, Nancy, France
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsing-onset multiple sclerosis according to the 2017 McDonald criteria
Blood and cerebrospinal fluid samples collected at diagnostic assessment from 2012 January 1st and kept in the Centre de Ressources Biologiques Lorrain
First platform disease modifying drugs : interferon-Beta, dimethyl fumarate or teriflunomide, introduced during the first 3 months after the diagnostic assessment
Disease modifying drugs maintained at least 3 months
Follow-up during at least 15 months after the first disease modifying drug initiation
At least one brain magnetic resonance imaging with gadolinium injection between months 3 and 15 after disease modifying drug initiation
You may not be if
Objection to the use of personal data for research purpose
Clareo Health | Multiple Sclerosis: Chi3L1 and Treatment Efficacy
